BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 35343063)

  • 1. Stereotactic radiosurgery for melanoma brain metastases: Concurrent immune checkpoint inhibitor therapy associated with superior clinicoradiological response outcomes.
    Shanker MD; Garimall S; Gatt N; Foley H; Crowley S; Le Cornu E; Muscat K; Soon W; Atkinson V; Xu W; Watkins T; Huo M; Foote MC; Pinkham MB
    J Med Imaging Radiat Oncol; 2022 Jun; 66(4):536-545. PubMed ID: 35343063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Local tumor response and survival outcomes after combined stereotactic radiosurgery and immunotherapy in non-small cell lung cancer with brain metastases.
    Singh C; Qian JM; Yu JB; Chiang VL
    J Neurosurg; 2019 Feb; 132(2):512-517. PubMed ID: 30771783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The combination of stereotactic radiosurgery with immune checkpoint inhibition or targeted therapy in melanoma patients with brain metastases: a retrospective study.
    Martins F; Schiappacasse L; Levivier M; Tuleasca C; Cuendet MA; Aedo-Lopez V; Gautron Moura B; Homicsko K; Bettini A; Berthod G; Gérard CL; Wicky A; Bourhis J; Michielin O
    J Neurooncol; 2020 Jan; 146(1):181-193. PubMed ID: 31836957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential role for LINAC-based stereotactic radiosurgery for the treatment of 5 or more radioresistant melanoma brain metastases.
    Frakes JM; Figura NB; Ahmed KA; Juan TH; Patel N; Latifi K; Sarangkasiri S; Strom TJ; Chinnaiyan P; Rao NG; Etame AB
    J Neurosurg; 2015 Nov; 123(5):1261-7. PubMed ID: 26140482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.
    Chen L; Douglass J; Kleinberg L; Ye X; Marciscano AE; Forde PM; Brahmer J; Lipson E; Sharfman W; Hammers H; Naidoo J; Bettegowda C; Lim M; Redmond KJ
    Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):916-925. PubMed ID: 29485071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Melanoma brain metastases treated with stereotactic radiosurgery and concurrent pembrolizumab display marked regression; efficacy and safety of combined treatment.
    Anderson ES; Postow MA; Wolchok JD; Young RJ; Ballangrud Å; Chan TA; Yamada Y; Beal K
    J Immunother Cancer; 2017 Oct; 5(1):76. PubMed ID: 29037215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Term Intracranial Outcomes With Combination Dual Immune-Checkpoint Blockade and Stereotactic Radiosurgery in Patients With Melanoma and Non-Small Cell Lung Cancer Brain Metastases.
    Vaios EJ; Shenker RF; Hendrickson PG; Wan Z; Niedzwiecki D; Winter SF; Shih HA; Dietrich J; Wang C; Salama AKS; Clarke JM; Allen K; Sperduto P; Mullikin T; Kirkpatrick JP; Floyd SR; Reitman ZJ
    Int J Radiat Oncol Biol Phys; 2024 Apr; 118(5):1507-1518. PubMed ID: 38097090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long duration of immunotherapy before radiosurgery might improve intracranial control of melanoma brain metastases.
    Fenioux C; Troussier I; Amelot A; Borius PY; Canova CH; Blais E; Mazeron JJ; Maingon P; Valéry CA
    Cancer Radiother; 2023 May; 27(3):206-213. PubMed ID: 37149466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic effects of immune checkpoint inhibitors in combination with stereotactic radiosurgery for patients with lung cancer and brain metastases: a propensity score-matched analysis.
    Yomo S; Oda K; Oguchi K
    J Neurosurg; 2023 Dec; 139(6):1628-1637. PubMed ID: 37243558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stereotactic radiosurgery with immune checkpoint inhibitors for brain metastases: a meta-analysis study.
    Badrigilan S; Meola A; Chang SD; Rezaeian S; Nemati H; Almasi T; Rostampour N
    Br J Neurosurg; 2023 Dec; 37(6):1533-1543. PubMed ID: 34979828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Local and distant brain control in melanoma and NSCLC brain metastases with concurrent radiosurgery and immune checkpoint inhibition.
    Le A; Mohammadi H; Mohammed T; Burney H; Zang Y; Frye D; Shiue K; Lautenschlaeger T; Miller J
    J Neurooncol; 2022 Jul; 158(3):481-488. PubMed ID: 35641840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic factors for survival in patients treated with stereotactic radiosurgery for recurrent brain metastases after prior whole brain radiotherapy.
    Caballero JA; Sneed PK; Lamborn KR; Ma L; Denduluri S; Nakamura JL; Barani IJ; McDermott MW
    Int J Radiat Oncol Biol Phys; 2012 May; 83(1):303-9. PubMed ID: 22079723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRAF V600E mutation and BRAF kinase inhibitors in conjunction with stereotactic radiosurgery for intracranial melanoma metastases.
    Xu Z; Lee CC; Ramesh A; Mueller AC; Schlesinger D; Cohen-Inbar O; Shih HH; Sheehan JP
    J Neurosurg; 2017 Mar; 126(3):726-734. PubMed ID: 27203149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcomes of melanoma brain metastases treated with nivolumab and ipilimumab alone versus nivolumab and ipilimumab with stereotactic radiosurgery.
    Tang JD; Mills MN; Nakashima J; Dohm AE; Khushalani NI; Forsyth PA; Vogelbaum MA; Wuthrick EJ; Yu HM; Oliver DE; Liu JKC; Ahmed KA
    J Neurooncol; 2024 Feb; 166(3):431-440. PubMed ID: 38310157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A matched-pair analysis comparing stereotactic radiosurgery with whole-brain radiotherapy for patients with multiple brain metastases.
    El Shafie RA; Celik A; Weber D; Schmitt D; Lang K; König L; Bernhardt D; Höne S; Forster T; von Nettelbladt B; Adeberg S; Debus J; Rieken S
    J Neurooncol; 2020 May; 147(3):607-618. PubMed ID: 32239433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery.
    Qian JM; Yu JB; Kluger HM; Chiang VL
    Cancer; 2016 Oct; 122(19):3051-8. PubMed ID: 27285122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiation necrosis with stereotactic radiosurgery combined with CTLA-4 blockade and PD-1 inhibition for treatment of intracranial disease in metastatic melanoma.
    Fang P; Jiang W; Allen P; Glitza I; Guha N; Hwu P; Ghia A; Phan J; Mahajan A; Tawbi H; Li J
    J Neurooncol; 2017 Jul; 133(3):595-602. PubMed ID: 28500560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stereotactic radiosurgery combined with nivolumab or Ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicity.
    Minniti G; Anzellini D; Reverberi C; Cappellini GCA; Marchetti L; Bianciardi F; Bozzao A; Osti M; Gentile PC; Esposito V
    J Immunother Cancer; 2019 Apr; 7(1):102. PubMed ID: 30975225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes after stereotactic radiosurgery of brain metastases in patients with malignant melanoma and validation of the melanoma molGPA.
    Kessel KA; Deichl A; Gempt J; Meyer B; Posch C; Diehl C; Zimmer C; Combs SE
    Clin Transl Oncol; 2021 Oct; 23(10):2020-2029. PubMed ID: 33993415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early imaging radioresponsiveness of melanoma brain metastases as a predictor of patient prognosis.
    Zubatkina I; Ivanov P
    J Neurosurg; 2018 Aug; 129(2):354-365. PubMed ID: 28841116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.